Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia

J Clin Pharm Ther. 2015 Jun;40(3):336-8. doi: 10.1111/jcpt.12251. Epub 2015 Mar 30.

Abstract

What is known and objective: Chemotherapy can increase treatment-related mortality associated with future haematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory acute myeloid leukaemia (AML). There is usually insufficient time to find a suitable unrelated donor for these patients. We report on the use of decitabine, a DNA methyltransferase inhibitor as a conditioning regimen for a patient undergoing HSCT.

Case summary: Our patient was a 21-year-old male diagnosed with AML-M1 with 84·5% blast cells and a normal karyotype. His risk stratum was intermediate, without specific mutations of FLT3/ITD, NPM1, CEBPA and C-kit. He underwent successful haploidentical HSCT using decitabine, a conditioning regimen.

What is new and conclusion: We present the first report of a patient with refractory AML (with 58% blast cells) treated successfully with decitabine as a conditioning regimen in haploidentical HSCT.

Keywords: conditioning regimen; decitabine; haploidentical stem cell transplantation; refractory acute myeloid leukaemia.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Azacitidine / administration & dosage
  • Azacitidine / analogs & derivatives*
  • Decitabine
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Nucleophosmin
  • Transplantation Conditioning / methods*
  • Treatment Outcome
  • Young Adult

Substances

  • Antimetabolites, Antineoplastic
  • NPM1 protein, human
  • Nucleophosmin
  • Decitabine
  • Azacitidine